围孕期妊娠用药暴露风险评价与药学实践进展  

Advances in risk assessment and pharmaceutical care of pregnancy medication exposure during perinatal period

作　　者：王然[1] 冯欣[1] 杜博冉[1] WANG Ran;FENG Xin;DU Boran(Department of Pharmacy,Beijing Obstetrics and Gynecology Hospital/Capital Medical University,Beijing Maternal and Child Health Care Hospital,Beijing 100026,China)

机构地区：[1]首都医科大学附属北京妇产医院/北京妇幼保健院药事部,北京100026

出　　处：《中国药物警戒》2023年第7期836-840,共5页Chinese Journal of Pharmacovigilance

基　　金：国家自然科学基金资助项目(72204170);北京市自然科学基金青年项目(7224354);北京市属医院科研培育计划(PZ2022028);北京市医院管理中心临床医学发展专项经费资助(ZYLX202119);首都医科大学附属北京妇产医院中青年学科骨干培养专项(FCYY201929)。

摘　　要：近年来,我国妊娠人群特点发生变化,孕期用药的比例相对较高,妊娠药物暴露风险也随之增加。围孕期药物暴露风险评价是保障孕期用药安全的重要内容。本文通过对围孕期药物暴露现状、药物与致畸风险及如何开展风险评价与药学服务等方面进行阐述,总结目前尚存的问题与挑战,为规范开展药学服务,完善我国风险评价体系提供参考。With the changes in Chinese pregnant populations in recent years,the proportion of medication during pre gnancy is relatively high,and the risk of exposure to drugs during pregnancy has also been increased.Therefore,risk assessment of drug exposure during pregnancy is critical to drug safety during pregnancy.This article reviews the cu rrent drug exposure during perinatal pregnancy,drugs and teratogenic risk,and ways to engage in risk assessment and pharmaceutical care before summarizing the problems and challenges so as to standardize the development of ph armaceutical care and provide reference for improving the risk assessment system in China.

关 键 词：孕产妇 围孕期 用药安全 药物暴露 妊娠期 风险评估 药学服务 

分 类 号：R969.3[医药卫生—药理学]